The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

By D. Cota, G. Marsicano, Matthias Tschöp, Y. Grübler, C. Flachskamm, M. Schubert, D. Auer, A. Yassouridis, C. Thöne-Reineke, S. Ortmann and 8 more. Journal of Clinical Investigation, 2003

1,230 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Endocrine and Autonomic Systems, Pharmacology

View Paper: https://www.semanticscholar.org/paper/efb141dcebd3ff546aca6a24b84eec283ee46b12

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

1. K. Mackie
2. George Kunos
3. V. Di Marzo

In Endocrine and Autonomic Systems

1. V. Di Marzo

In Pharmacology

1. V. Di Marzo
2. George Kunos
3. P. Pacher
4. S. Batkai
5. K. Mackie
6. G. Marsicano
7. P. Greasley
8. B. Lutz

Citations in the corpus

• The Human Obesity Gene Map: The 2005 Update (2006, background): “9) Cnr1 6q14-q15 CNR1 Cannabinoid receptor 1 (brain), also known as CB1 receptor Floxed gene ubiquitously expressed Cre Reduced adiposity (338) Human Obesity Gene Map: The 2005 Update, Rankinen et al.”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “…affect lipid metabolism through regulating the level of adiponectin production (Bensaid et al., 2003), by increasing lipoprotein lipase activity (Cota et al., 2003), or by inhibiting AMPactivated protein kinase (AMPK) (Kola et al., 2005), which leads to increased lipogenesis and decrease in…”
• Endocannabinoid control of food intake and energy balance (2005, background): “CB 1 receptors colocalize with corticotropin-releasing hormone (CRH) in the paraventricular nucleus (PVN), with melanin-concentrating hormone in the lateral hypothalamus, and with pre-pro-orexin in the ventromedial hypothalamu”
• Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. (2006, background): “White adipocytes do express functional CB1 receptors, whose levels are higher in obese rats and whose blockade leads to increased levels of adiponectin (13, 17), an adipokine that enhances insulin sensitivity and glucose and lipid metabolism (18).”
• The endocannabinoid system and its therapeutic exploitation (2004, neutral): “, or to minimize the impact of the stressful stimulus by reinforcing appetite through inhibition of anorectic signal”
• The emerging role of the endocannabinoid system in endocrine regulation and energy balance. (2006, background): “expression at the level of the adipose tissue (58, 59), we can”
• The orphan receptor GPR55 is a novel cannabinoid receptor (2007, background): “Recently, the liver and adipose has been added to the list (Cota et al., 2003; Osei-Hyiaman et al., 2005).”
• Activation of the peripheral endocannabinoid system in human obesity. (2005, background): “These data suggest that peripheral mechanisms are also involved in the control of body weight by endocannabinoids and led to the discovery of CB-1 receptor gene expression in rodent adipocytes (16,17).”
• Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. (2005, background): “Body weight at the start of the diet was slightly, but significantly, lower in CB1 mice than in their CB1 littermates, in agreement with published results (17).”
• The endocannabinoid system links gut microbiota to adipogenesis (2010, background): “…CB1 receptor activation is known to increase lipogenesis-induced lipid accumulation in both liver (OseiHyiaman et al, 2005, 2008) and fat cells (Cota et al, 2003; Bouaboula et al, 2005; Gary-Bobo et al, 2006; Matias et al, 2006; Bellocchio et al, 2008; Pagano et al, 2008), we investigated…”